Jeffrey Viar
Family Medicine · Columbus, NCNPI 1811998271
Payments from drug & device makers
Across 215 payments — averaging $20.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$510
- AbbVie$490
- Amgen$404
- AstraZeneca$402
- Novartis$343
- Novo Nordisk$290
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,33598%
- Education$1052%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 24 | $510 |
| AbbVie | 31 | $490 |
| Amgen | 20 | $404 |
| AstraZeneca | 16 | $402 |
| Novartis | 13 | $343 |
| Novo Nordisk | 15 | $290 |
| GSK | 11 | $260 |
| Boehringer Ingelheim | 10 | $195 |
| Pfizer | 6 | $152 |
| Boston Scientific | 5 | $135 |
| Johnson & Johnson | 4 | $128 |
| Sanofi-aventis U.S. LLC | 5 | $113 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $111 |
| Bayer | 6 | $104 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $89 |
| Teva Pharmaceuticals USA, Inc. | 4 | $74 |
| Astellas Pharma US Inc | 4 | $70 |
| Otsuka America Pharmaceutical, Inc. | 3 | $66 |
| Philips North America LLC | 2 | $60 |
| Paratek Pharmaceuticals, Inc. | 3 | $57 |
| Heartflow, Inc. | 2 | $49 |
| Abbott | 2 | $47 |
| Idorsia Pharmaceuticals US Inc | 2 | $44 |
| Corium, LLC | 4 | $42 |
| Antares Pharma, Inc. | 2 | $33 |
| Cvrx, Inc. | 1 | $31 |
| Merck | 2 | $30 |
| Edwards Lifesciences | 1 | $29 |
| Dexcom, Inc. | 1 | $24 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Smith+Nephew | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 1 | $10 |
| Forte Bio-pharma LLC | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,440 in reported general payments places this provider in the 85th percentile of 3,444 family medicine providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 251 | $143,360 |
| OzempicSemaglutide | 111 | $125,957 |
| JardianceEmpagliflozin | 125 | $89,670 |
| MounjaroTirzepatide | 72 | $82,658 |
| XareltoRivaroxaban | 108 | $67,543 |
| TrulicityDulaglutide | 31 | $46,322 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $42,380 |
| LinzessLinaclotide | 43 | $25,011 |
| Tresiba Flextouch U-100Insulin Degludec | 61 | $18,544 |
| FarxigaDapagliflozin Propanediol | 22 | $15,955 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $15,476 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $14,252 |
| EntrestoSacubitril/Valsartan | 16 | $13,590 |
| MyrbetriqMirabegron | 21 | $11,409 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $10,570 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $152 | $143,360251 claims |
| Lilly USA, LLCMounjaro, Trulicity | $510 | $128,980103 claims |
| Novo NordiskOzempic | $290 | $125,957111 claims |
| Boehringer IngelheimJardiance | $195 | $89,670125 claims |
| Johnson & JohnsonXarelto | $128 | $67,543108 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $260 | $62,72896 claims |
| AbbVieLinzess, Synthroid | $490 | $31,076131 claims |
| AstraZenecaFarxiga, Symbicort | $402 | $19,16634 claims |
| NovartisEntresto | $343 | $13,59016 claims |
| Astellas Pharma US IncMyrbetriq | $70 | $11,40921 claims |
| MerckJanuvia | $30 | $8,94915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Columbus
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
- Stephen JonesShelby$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.